NEW YORK (GenomeWeb) – Protagen announced today that it has partnered with the National Cancer Institute to identify and test biomarkers of patient response to cancer immunotherapy.
Under the terms of their material transfer agreement, the collaborators will use Protagen's SeroTag platform — which measures autoantibody levels for thousands of antigens simultaneously — to identify biomarkers that predict immunotherapy responsiveness, monitor patients receiving treatment, and for the early detection of immune-related adverse events.
Additional terms of the deal were not disclosed.
The SeroTag technology "has already proven that it can be used to accurately monitor the status of patients with autoimmune disease and segregate these complex diseases in homogeneous patient groups with the potential to predict treatment response," Protagen CSO Peter Schulz-Knappe said in a statement. "Given the links between immunotherapy and autoimmune disease, it will be a natural extension to apply our approach to immuno-oncology and address some of the most pressing questions and challenges in the field."
Protagen's deal with the NCI comes less than a month after the company struck a similar arrangement with the German National Center for Tumor Diseases Heidelberg.